Editor: What To Know
- Wright, MiMedx Chief Executive Officer, commented, “As a pioneer in the development of placental tissue technology, MiMedx is constantly improving our knowledge of placental science – as a unique biological system that supports growth and healing – to elevate the standard of care and help bring hope and relief to the millions suffering with chronic and hard-to-heal wounds.
- Healthcare professionals are looking for added versatility when addressing larger, hard-to-heal wounds, and the new EpiCord Expandable provides a versatile and flexible option to help meet this urgent patient need for those who may require specific interventions to restart the healing process.
- With an aging population and rapidly growing number of people with diabetes, new applications of placental-tissue science like EpiCord Expandable will help to meet public health needs and advance the field.
September 14, 2020
EpiCord Expandable Placental Allograft has been launched. The news was announced today by MiMedx.
EpiCord Expandable Placental Allograft allows the allograft to cover up to twice the surface area once expanded. This new placental tissue allograft provides healthcare professionals an additional option to support the advanced wound care needs of their patients with larger, chronic, and hard-to-heal wounds.
“There is growing demand for advanced interventions in the treatment of chronic wounds,” said Dr. Bill Tettelbach, MiMedx Principal Medical Officer. “Many are unaware that about 20 percent of moderate-to-severe diabetic foot ulcers lead to amputation. When people with diabetes have a non-traumatic below the knee amputation, their mortality rate can exceed 70 percent at five years. Treatment of these patients is aimed at healing the wound, saving their limb and improving their quality of life. Healthcare professionals are looking for added versatility when addressing larger, hard-to-heal wounds, and the new EpiCord Expandable provides a versatile and flexible option to help meet this urgent patient need for those who may require specific interventions to restart the healing process.”
More than 30 million Americans are living with diabetes and the numbers continue to increase. Of those with diabetes, 2.9 million of them suffer from chronic wounds. Data show that the cost of treating chronic wounds in the United States is rising sharply, exceeding an estimated $28 billion annually.
Timothy R. Wright, MiMedx Chief Executive Officer, commented, “As a pioneer in the development of placental tissue technology, MiMedx is constantly improving our knowledge of placental science – as a unique biological system that supports growth and healing – to elevate the standard of care and help bring hope and relief to the millions suffering with chronic and hard-to-heal wounds. With an aging population and rapidly growing number of people with diabetes, new applications of placental-tissue science like EpiCord Expandable will help to meet public health needs and advance the field.”
